0001062822-21-000042.txt : 20210730 0001062822-21-000042.hdr.sgml : 20210730 20210730075200 ACCESSION NUMBER: 0001062822-21-000042 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210730 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210730 DATE AS OF CHANGE: 20210730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 211130077 BUSINESS ADDRESS: STREET 1: 2445 TECHNOLOGY FOREST BLVD. STREET 2: SUITE 1100 CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 2445 TECHNOLOGY FOREST BLVD. STREET 2: SUITE 1100 CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE DATE OF NAME CHANGE: 20070426 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 8-K 1 lxrx-20210730.htm 8-K lxrx-20210730
0001062822FALSE00010628222021-07-302021-07-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________

FORM 8-K
__________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2021

Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware000-3011176-0474169
(State or other jurisdiction of
incorporation or organization)		(Commission File Number)(I.R.S. Employer
Identification Number)

2445 Technology Forest Blvd., 11th Floor
The Woodlands, Texas 77381
(Address of principal executive offices and Zip Code)

(281) 863-3000
(Registrant’s telephone number, including area code)

8800 Technology Forest Place
The Woodlands, Texas 77381
(Former address if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001LXRXThe Nasdaq Global Select Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02    Results of Operation and Financial Condition

On July 30, 2021, we issued a press release to report our financial results for the quarter ended June 30, 2021. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.


Item 9.01    Financial Statements and Exhibits

(d)    Exhibits

Exhibit No.Description
99.1—
EX-104—Cover Page Interactive Data File (embedded within the Inline XBRL document)



Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lexicon Pharmaceuticals, Inc.
Date: July 30, 2021By:/s/ Brian T. Crum
Brian T. Crum
Vice President and General Counsel




 EX-101.SCH 2 lxrx-20210730.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 lxrx-20210730_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 4 lxrx-20210730_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 lxrx-20210730_htm.xml IDEA: XBRL DOCUMENT 0001062822 2021-07-30 2021-07-30 0001062822 false 8-K 2021-07-30 Lexicon Pharmaceuticals, Inc. DE 000-30111 76-0474169 2445 Technology Forest Blvd., 11th Floor The Woodlands TX 77381 281 863-3000 The Woodlands TX 77381 Common Stock, par value $0.001 LXRX NASDAQ false false false false false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Jul. 30, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 30, 2021
Entity Registrant Name Lexicon Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 000-30111
Entity Tax Identification Number 76-0474169
Entity Address, Address Line One 2445 Technology Forest Blvd., 11th Floor
Entity Address, City or Town The Woodlands
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77381
City Area Code 281
Local Phone Number 863-3000
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol LXRX
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001062822
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.lexpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports lxrx-20210730.htm lxrx-20210730.xsd lxrx-20210730_lab.xml lxrx-20210730_pre.xml pressreleaseearnings2021-0.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lxrx-20210730.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "lxrx-20210730.htm" ] }, "labelLink": { "local": [ "lxrx-20210730_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "lxrx-20210730_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "lxrx-20210730.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lxrx", "nsuri": "http://www.lexpharma.com/20210730", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20210730.htm", "contextRef": "i9afdd000543b43eaa7a0022831dd5596_D20210730-20210730", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.lexpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lxrx-20210730.htm", "contextRef": "i9afdd000543b43eaa7a0022831dd5596_D20210730-20210730", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lexpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001062822-21-000042-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001062822-21-000042-xbrl.zip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